Articles: Pharmaceutical/Generics

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles
Browse

Articles

Displaying 1..10 of 11 - per page Next page
Order by

The major pharmaceutical markets like North America, Europe and Japan are facing a very sluggish growth. More

Generics: moving up the value chain to higher priced products

Neil Turner of PPR Communications, a division of IMS Health, reports on why big pharma is getting into generics and how generic companies are moving up the value chain. More

Generics flourish as innovation stalls

Generics have become an integral part of the growth machine of the pharmaceutical industry, leading figures from IMS Health underlined during the DCAT meeting held in New York in March 2004 More

How to grow your generic business through licensing partnerships

In the business world there are two main ways to increase revenue; sell more of the products you have or find new products to sell. More

Genus Pharmaceuticals: A little big company

Genus Pharmaceuticals has recently became the wholly owned UK subsidiary of STADA Arzneimittel AG, a German company with a large portfolio of existing generic drugs, as well as an impressive number in its pipeline. More

Authorized generics: To switch rather than fight

Do the compromises of Hatch-Waxman need a further look? More

Compliance issues for innovator and generic biopharmaceuticals, Part 2: What could change?

The FDA has significant concerns about potential contamination, including cross-contamination, of biotech products. More

Foresight or folly? Generics firms' foray into NCEs

A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. More

Close Enough?

The prospect of off-patent blockbuster biotechnology drugs is More

Compliance issues for innovator and generic biopharmaceuticals, Part 1: Expectations and observations

For decades, biologic products constituted a small segment of the pharmaceutical industry that drew little attention. But conferences exploring various facets of generic biologics have become common in recent years. More

Displaying 1..10 of 11 - per page Next page
Order by

Your selection

Industry sector: Pharmaceutical del; Generics del

Browse By

Therapeutic target: Accident and Trauma; Allergy; Blood and forming organs; Cardiovascular; Central Nervous System; Dermatological; Endocrinology; Gastrointestinal; Genetic disorders; Genito-urinary; Hospital and Surgery; Immune related disorders; Infectious diseases; Metabolism; Musculoskeletal; Oncology; Oral Health; Other therapeutic; Respiratory; Sensory organ
Year: 2009; 2008; 2007; 2006; 2005; 2004; 2003; 2002; 2001; 2000; 1999

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us